Role of Hydralazine 25mg in Treatment of Hypertensive Patients at a Tertiary Care Hospital

Amjad Mustafa; Shabir Hussain; Arif Mumtaz; Ghazala Shaheen; Asif Ullah; Fawad Qaiser

doi:10.29054/apmc/2022.1016

Amjad Mustafa Associate Professor, Department of Pharmacology, Khyber Medical University Institute of Medical Sciences (KMU-IMS), Kohat Pakistan
Shabir Hussain Associate Professor, Department of Pharmacology, Bannu Medical College, Bannu Pakistan
Arif Mumtaz Associate Professor, Department of Medicine, Khyber Medical University Institute of Medical Sciences (KMU-IMS), Kohat Pakistan
Ghazala Shaheen Assistant Professor, Department of Pharmacology, Khyber Medical University Institute of Dental Sciences (KMU-IDS), Kohat Pakistan
Asif Ullah Associate Professor, Department of Cardiology, Khyber Medical University Institute of Medical Sciences (KMU-IMS), Kohat Pakistan
Fawad Qaiser Demonstrator, Department of Pharmacology, Khyber Medical University Institute of Medical Sciences (KMU-IMS), Kohat Pakistan

DOI: https://doi.org/10.29054/apmc/2022.1016

Keywords: Hydralazine, Biochemical effects, Hypertension, Treatment

Abstract

Background: Managing blood pressure in patients with hypertension remains a therapeutic issue that frequently necessitates the use of secondary medicines to primary therapy. Objective: To determine role of hydralazine 25mg in treatment of hypertensive patients at a tertiary care hospital. Design: Case-control comparative study. Setting: Department of Pharmacology DHQ Teaching Hospital kohat and Khaleefa Gul Nawaz Teaching Hospital, Bannu Pakistan. Duration: Study duration was six months from June 2021 to November 2021. Methods: In this study, 80 patients were enrolled, while 20 patients kept in control and 6o in treatment group. For both groups, one group received Hydralazine 25mg and the other group received a, blood pressure was assessed at baseline and eight weeks later for both groups. For both groups, biochemical safety variables were measured. SPSS 25.0 was used for statistical analysis of all the data. Results: Systolic blood pressure was 146.7 + 9.1 at baseline for Hydralazine 25mg and 147.5 + 9.9 for the control. After 8 weeks, the difference between the two treatments (control and Hydralazine 25mg) was 139.9 9.8. For Hydralazine 25mg, the baseline diastolic blood pressure was 98.5 + 5.2, while it was 95.8 + 7.8 for the control. After 8 weeks, the results for the control were 97.1 4.7 and were 87.4 6.1 for Hydralazine 25mg. Conclusion: For eight weeks, hydralazine 25mg produced the best results for achieving and maintaining blood pressure. It is the greatest option for BP patients because of its excellent antihypertensive efficacy, and people with metabolic syndrome can use it safely.